Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
BioCapital Holdings is a Houston-based synthetic biology company that develops biotechnology prototyping and bio-manufacturing systems. The company specializes in modifying yeast and bacteria DNA to create "genetic devices" capable of fermenting sustainable, non-GMO compounds for industrial and medical applications. Utilizing a unique Special Purpose Entity (SPE) business model, the company licenses its technology for diverse uses, including needle-free diagnostic sensors for glucose and concussions, as well as agricultural and cosmetic products. With a portfolio of over 25 patents, BioCapital Holdings aims to provide cost-efficient, scalable biological production while avoiding the lengthy regulatory hurdles typical of traditional pharmaceutical development. The company's platform also integrates Agentic AI for yield optimization and rapid prototyping of biochemical materials.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on BioCapital Holdings.